stockportfolio.pro
Syndax Pharmaceuticals, Inc. (SNDX)
Healthcare · Biotechnology · NasdaqGS
Syndax Pharmaceuticals, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.22M | $2.11M | $1.52M | $1.52M | $1.52M | $139.71M | $0 | $0 | $23.68M | $172.35M |
| Gross profit | — | — | — | — | — | — | — | — | $22.85M | $165.38M |
| Net income | $-44.47M | $-60.80M | $-73.96M | $-56.05M | $-73.16M | $24.93M | $-149.34M | $-209.36M | $-318.76M | $-285.42M |
| Net margin | -3645.2% | -2884.3% | -4875.5% | -3694.6% | -4822.5% | 17.8% | — | — | -1346.1% | -165.6% |
Source: Syndax Pharmaceuticals, Inc. SEC filings (10-K). 12 years of history available in the interactive view.
Explore 12 years of Syndax Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SNDX in your portfolio →
Syndax Pharmaceuticals, Inc. financial history by metric
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Syndax Pharmaceuticals, Inc. — frequently asked questions
What is Syndax Pharmaceuticals, Inc.'s revenue?
Syndax Pharmaceuticals, Inc. (SNDX) reported revenue of $172.35M for fiscal year 2025, up 627.8% from the prior year, according to its SEC filings.
Is Syndax Pharmaceuticals, Inc. profitable?
No — SNDX reported a net loss of $-285.42M in fiscal 2025.
What is SNDX's P/E ratio?
Syndax Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Syndax Pharmaceuticals, Inc. growing?
SNDX's revenue grew at roughly 157.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Syndax Pharmaceuticals, Inc. have?
As of fiscal year 2025, SNDX carried roughly $687.82M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Syndax Pharmaceuticals, Inc.'s gross margin?
SNDX's gross margin was 96.0% in fiscal 2025 — gross profit of $165.38M on revenue of $172.35M.
What is Syndax Pharmaceuticals, Inc.'s market cap?
Syndax Pharmaceuticals, Inc. (SNDX) has a market capitalization of about $1.59B, based on the latest data in our nightly-refreshed cache.
When does Syndax Pharmaceuticals, Inc.'s fiscal year end?
SNDX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Syndax Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 12 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.